Lars-Christian Horn1, Anne Kathrin Höhn2, Irene Krücken3, Mathias Stiller3, Ulrike Obeck3, Christine E Brambs4. 1. Division of Gynecologic, Breast and Perinatal Pathology, Institute of Pathology, University Hospital Leipzig, Liebigstrasse 26, 04103, Leipzig, Germany. hornl@medizin.uni-leipzig.de. 2. Division of Gynecologic, Breast and Perinatal Pathology, Institute of Pathology, University Hospital Leipzig, Liebigstrasse 26, 04103, Leipzig, Germany. 3. Division Molecular Pathology, Institute of Pathology, University Hospital Leipzig, Leipzig, Germany. 4. Department of Obstetrics and Gynecology, Technical University Munich, Munich, Germany.
Abstract
PURPOSE: Endometrial mesonephric-like adenocarcinoma (ML-AC) represents a recently recognized subtype of endometrial adenocarcinoma (AC) associated with a subtle immunophenotype with a characteristic KRAS-mutation. Detailed clinico-pathologic analyses and prognostic data on ML-AC are limited. METHODS: We report a series of four cases with histopathological, immunohistochemical, and molecular analyses. These cases as well as the data of previously published cases were reviewed for clinico-pathologic variables and clinical follow-up information. RESULTS: Forty cases of ML-AC were identified. ML-AC represents about 1% of all endometrial carcinomas. Similar to other types of endometrial AC, vaginal bleeding was the leading presenting symptom, and the mean age was 60.0 years (range 31-91). More than a half of the patients presented with locally advanced disease (≥ FIGO stage II) at time of diagnosis, developed a recurrence or died of the disease within a mean follow-up period of 24.7 months (range 3-144.5 months). The most common site of distant disease was pulmonary involvement. Microscopically, ML-ACs present with mixed morphology and show a co-expression of so-called mesonephric and Müllerian markers, suggesting a Müllerian origin of the tumors. Immunostaining for PD-L1 was negative in all tested cases, using different antibodies against PD-L1. Retained staining for mismatch repair proteins on immunohistochemistry and a POLE-mutation suggest a copy number low phenotype within the molecular classification of endometrial carcinomas. Almost all cases showed a KRAS-mutation at codon 12 (mostly G12V). CONCLUSION: Uterine ML-AC represents a distinct subtype of invasive endometrial AC, associated with KRAS-mutations and characteristic immunohistochemical findings. Clinically, ML-AC may show an aggressive behavior with a high rate of recurrent disease and a substantial risk for distant metastatic disease, especially to the lungs.
PURPOSE: Endometrial mesonephric-like adenocarcinoma (ML-AC) represents a recently recognized subtype of endometrial adenocarcinoma (AC) associated with a subtle immunophenotype with a characteristic KRAS-mutation. Detailed clinico-pathologic analyses and prognostic data on ML-AC are limited. METHODS: We report a series of four cases with histopathological, immunohistochemical, and molecular analyses. These cases as well as the data of previously published cases were reviewed for clinico-pathologic variables and clinical follow-up information. RESULTS: Forty cases of ML-AC were identified. ML-AC represents about 1% of all endometrial carcinomas. Similar to other types of endometrial AC, vaginal bleeding was the leading presenting symptom, and the mean age was 60.0 years (range 31-91). More than a half of the patients presented with locally advanced disease (≥ FIGO stage II) at time of diagnosis, developed a recurrence or died of the disease within a mean follow-up period of 24.7 months (range 3-144.5 months). The most common site of distant disease was pulmonary involvement. Microscopically, ML-ACs present with mixed morphology and show a co-expression of so-called mesonephric and Müllerian markers, suggesting a Müllerian origin of the tumors. Immunostaining for PD-L1 was negative in all tested cases, using different antibodies against PD-L1. Retained staining for mismatch repair proteins on immunohistochemistry and a POLE-mutation suggest a copy number low phenotype within the molecular classification of endometrial carcinomas. Almost all cases showed a KRAS-mutation at codon 12 (mostly G12V). CONCLUSION: Uterine ML-AC represents a distinct subtype of invasive endometrialAC, associated with KRAS-mutations and characteristic immunohistochemical findings. Clinically, ML-AC may show an aggressive behavior with a high rate of recurrent disease and a substantial risk for distant metastatic disease, especially to the lungs.
Authors: Edaise M da Silva; Daniel J Fix; Ana Paula Martins Sebastiao; Pier Selenica; Lorenzo Ferrando; Sarah H Kim; Anthe Stylianou; Arnaud Da Cruz Paula; Fresia Pareja; Evan S Smith; Ahmet Zehir; Jason A Konner; Karen Cadoo; Jorge S Reis-Filho; Nadeem R Abu-Rustum; Jennifer J Mueller; Britta Weigelt; Kay J Park Journal: Mod Pathol Date: 2021-03-26 Impact factor: 7.842
Authors: Jennifer Pors; Sheila Segura; Derek S Chiu; Noorah Almadani; Hezhen Ren; Daniel J Fix; Brooke E Howitt; David Kolin; W Glenn McCluggage; Jelena Mirkovic; Blake Gilks; Kay J Park; Lynn Hoang Journal: Am J Surg Pathol Date: 2021-04-01 Impact factor: 6.298
Authors: Pavel Dundr; Mária Gregová; Kristýna Němejcová; Michaela Bártů; Nikola Hájková; Jan Hojný; Ivana Stružinská; Daniela Fischerová Journal: Diagn Pathol Date: 2020-07-21 Impact factor: 2.644